Equity Compensation in the Age of Boston’s Biotech and Tech Boom
Greater Boston is home to one of the country’s largest concentrations of biotech and technology companies, from the lab campuses of Kendall Square in Cambridge to the corporate offices lining Route 128 to the Seaport District. Massachusetts companies account for 17% of the nation’s drug development pipeline, according to the Massachusetts Biotechnology Council’s 2026 Industry Snapshot. For many employees at these companies, a meaningful share of total compensation doesn’t show up as salary at all.
It arrives as restricted stock units, incentive stock options, or nonqualified stock options, each with its own vesting schedule, tax treatment, and set of decisions to make. Managing equity compensation can have a meaningful effect on a family’s broader financial picture, particularly when equity represents a significant portion of compensation or net worth.
Equity compensation planning for Greater Boston employees looks different from a financial plan built around salary and a 401(k) alone. With multiyear vesting schedules, alternative minimum tax exposure, and company stock that can quickly become a disproportionate share of a household’s net worth, these decisions tend to work better as part of a coordinated plan rather than a series of one-off choices made at tax time.
Why Equity Compensation Looks Different for Greater Boston’s Biotech and Tech Employees
Equity compensation looks different for Greater Boston’s biotech and tech employees because so much of it arrives in forms that change value over time, vest on a schedule outside an employee’s control, and carry tax rules most households don’t think about. A salaried employee generally knows what a paycheck will look like months in advance. An employee with unvested RSUs or outstanding stock options effectively holds a financial position whose value depends on where the stock trades on a given vesting date.
This is true across the region, whether someone works in Cambridge, a Route 128 tech campus, or a smaller company headquartered farther out. The core questions tend to be the same regardless of employer: when to exercise options, how much company stock to hold versus sell, and how to fit these decisions into a broader financial plan rather than treating each vesting date or exercise decision as its own isolated event.
How Do RSU Vesting Schedules Shape Your Financial Year at a Route 128 Biotech or Tech Company?
RSU vesting schedules shape your financial year by creating predictable moments, often quarterly, when a chunk of company stock becomes yours and becomes taxable, whether or not you sell it. Many tech and biotech employers spread RSU vesting over three or four years, frequently with a portion vesting every quarter after the first year. As a result, an employee’s income and tax bill can look meaningfully different from one quarter to the next. A financial advisor in Woburn, MA, close to the Route 128 corridor’s concentration of tech and biotech employers, sees this pattern often: a single vesting quarter that meaningfully changes a household’s income for the year.
Pre-IPO and newly public biotech and tech companies often use double-trigger vesting, meaning employees receive their RSUs only after meeting a time-based requirement and experiencing a liquidity event, such as an IPO. This structure is common enough across the region that it’s worth confirming exactly how your company structured your grant rather than assuming it works like a typical time-based vesting schedule.
The IRS treats RSU income as ordinary income at vesting, according to IRS Publication 525. Many employers withhold at a flat supplemental rate set by the IRS in Publication 15, and that rate doesn’t always match an employee’s actual bracket. As a result, a household in a higher tax bracket can end up owing more than expected at filing time, even though the employer technically withheld taxes all year. Reviewing upcoming vesting dates as part of an annual tax and cash flow review can help catch this gap before it becomes a surprise.
Some Greater Boston employers also pair RSU grants with an employee stock purchase plan, letting employees buy company stock at a discount through payroll deductions. Reviewing how an employee stock purchase plan works can help a family decide whether to fold that discount into the same diversification conversation as any RSUs or options already on the table.
Why Don’t ISOs and NSOs Get the Same Tax Treatment in Massachusetts?
ISOs and NSOs don’t get the same tax treatment because the tax code treats them as fundamentally different types of grants. One is designed to potentially qualify for favorable long-term capital gains treatment, and the other works more like a cash bonus at exercise. The two most common types employees encounter are:
- Incentive stock options (ISOs). Available only to employees under Section 422 of the Internal Revenue Code, ISOs can qualify for long-term capital gains treatment on the entire spread if the employee holds the shares at least two years from the grant date and one year from the exercise date. However, exercising and holding the shares can trigger the alternative minimum tax in the year of exercise, which is worth modeling before deciding whether to exercise and hold or exercise and sell right away.
- Nonqualified stock options (NSOs). Available to employees, board members, and consultants alike, NSOs create ordinary income at exercise. The IRS taxes the spread between the exercise price and the market price as ordinary income, and payroll taxes apply, regardless of how long the employee holds the shares afterward, according to IRS Publication 525. That makes the exercise itself the main event to plan around rather than the eventual sale.
A tax-focused review that models exercise timing against a family’s other income can help clarify which shares to exercise, and when, particularly in a year when income from RSU vesting, a bonus, or other equity compensation is already elevated. Understanding how incentive stock options interact with the alternative minimum tax matters just as much as understanding how the IRS taxes nonqualified stock options at exercise, since many employees hold both types of grants at different points in their career and need to treat each accordingly.
Employees at younger, venture-backed biotech and tech companies may also want to look into qualified small business stock, or QSBS. Under Section 1202 of the Internal Revenue Code, eligible QSBS may qualify for an exclusion of some or all of the gain from federal income tax, subject to numerous statutory requirements and limitations. Reviewing the rules for exercising options and the other requirements for QSBS treatment early can help employees evaluate potential eligibility before an exercise or sale.
What Happens When Company Stock Becomes Too Large a Share of a Greater Boston Employee’s Net Worth
Company stock becomes too large a share of a household’s net worth more often than most employees realize, since RSU grants, option exercises, and an employer’s rising stock price can all compound together over just a few years at the same company. Families working with a financial advisor in Wellesley, MA, often arrive at this conversation after a strong run in their employer’s stock, once a position that started small has quietly become a much larger share of their overall net worth than they intended. It’s a common pattern in Greater Boston’s biotech and tech sectors, where strong company performance can leave an employee with a large, concentrated position without ever making an active decision to build one.
That concentration carries real risk. A single company’s stock, however strong its prospects, can decline sharply on a clinical trial result, a product delay, or a broader sector pullback, in ways that tend to affect a diversified portfolio less. Reviewing how to diversify out of a concentrated tech stock position can help a family think through a gradual, tax-aware approach rather than an all-or-nothing decision. An investment management approach built around a family’s full picture, including outstanding equity compensation, can help determine how much company stock is reasonable to hold going forward and how quickly to work down the rest.
Planning Around an IPO or Direct Listing in Boston’s Biotech Sector
Planning around an IPO or direct listing in Boston’s biotech sector often means dealing with a sudden shift in liquidity and tax exposure, sometimes within the same calendar year. Employees who have held illiquid shares or options for years can suddenly find themselves able to sell, often for the first time, while also facing lock-up periods, blackout windows, and a concentrated tax bill they haven’t had to plan for before.
Because biotech stocks can swing sharply on clinical and regulatory news, a plan for what to do in the weeks and months after a lock-up expires matters just as much as the decisions made before the IPO itself. Employees who exercise stock options early, before they’re fully vested, should also keep the 30-day window for filing an 83(b) election in mind, a deadline set by Section 83 of the Internal Revenue Code. Missing it forecloses the opportunity to make the election, which can change the timing and amount of income recognized for tax purposes and can carry both potential benefits and risks. Waiting to make every decision until the lock-up period ends can leave a family reacting to a stock price rather than following a plan set in advance.
How Westwood Executives Align Equity Compensation with Long-Term Goals
A financial advisor in Westwood, MA, often sees executives aligning equity compensation with long-term goals by treating it as one input into a broader plan rather than a separate reward to manage on its own. That means weighing option exercises, RSU sales, and deferred compensation elections against retirement timing, education funding, and a family’s overall risk tolerance, not just against the current stock price.
Westwood executives working through a broader compensation strategy often find that once they treat equity compensation as part of the whole plan, individual decisions, like when to exercise or how much stock to sell in a given year, become easier to make with the rest of the picture already in view.
Structuring a Financial Plan for Biotech and Tech Employees Across the Boston Area
A financial plan built only around salary and a 401(k) can miss both the opportunity and the risk that come with equity compensation. A more complete approach looks at vesting schedules, option exercise timing, and concentration risk together, and asks how each decision affects cash flow, taxes, and long-term savings goals in the same year, not in isolation.
A coordinated financial plan can help a family map out vesting events for the next several years alongside other goals, so that a large vesting quarter becomes an opportunity to fund a goal, like a home purchase or a child’s education, rather than just a tax bill to manage.
What Tax Considerations Deserve a Second Look Before Your Next Vesting Date in Massachusetts?
Tax considerations deserve a second look before your next vesting date because RSU and stock option income can push a household into a higher bracket for the year, affect estimated tax payment requirements, and interact with other equity compensation vesting around the same time. Employees who hold grants from more than one employer, or who have both older ISOs and newer RSUs vesting, face an even more layered picture.
Timing option exercises across calendar years, when possible, can help manage how much ordinary income or AMT exposure lands in a single tax year. Coordinating estimated tax payments ahead of a known vesting date, rather than waiting to react at filing time, can also help reduce the risk of an underpayment penalty on top of an already elevated tax bill.
When Should You Bring in a Fiduciary Financial Advisor for Equity Compensation in Greater Boston?
The right time to bring in a fiduciary financial advisor is usually before a major vesting event, an option exercise decision, or an IPO and its lock-up expiration. Changing employers, whether by choice or not, belongs on that list, too. People leaving a job tend to focus closely on their equity: what they’re forfeiting, what they can keep, and whether a new employer will make up for unvested RSUs and options through a sign-on grant or cash buyout.
A departure can also force those decisions onto a much shorter timeline. To keep ISO tax treatment, employees must generally exercise vested ISOs within three months of leaving, under Section 422. After that, the options either expire or, if the plan allows a later exercise, receive NSO tax treatment, which changes the tax treatment discussed earlier in this article.
A financial advisor familiar with equity compensation across Greater Boston’s biotech and tech employers can help a family model exercise and diversification decisions ahead of time, coordinating tax, investment, and financial planning so that the family makes no single decision without seeing how it affects the rest of the picture.
Work with Savant Wealth Management in Greater Boston
Equity compensation can be one of the most valuable parts of working for a Greater Boston biotech or tech company, but only when employees plan for it rather than leaving it to sort itself out. Savant Wealth Management provides financial planning, tax planning, and investment management support that may help Greater Boston employees turn RSUs, stock options, and concentrated positions into one coordinated plan. Schedule an introductory call today to talk through how your equity compensation fits into your broader financial picture.
This is intended for informational purposes only. You should not assume that any discussion or information contained in this document serves as the receipt of, or as a substitute for, personalized investment or tax advice from Savant. Please consult your investment or tax professional regarding your unique situation.